CeriBell, Inc. (NASDAQ:CBLL) Receives $23.20 Average PT from Brokerages

CeriBell, Inc. (NASDAQ:CBLL) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $23.20.

CBLL has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of CeriBell in a research note on Monday, April 6th.

Insider Activity at CeriBell

In related news, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00. Following the completion of the transaction, the chief executive officer owned 850,347 shares in the company, valued at approximately $15,646,384.80. This represents a 4.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the completion of the sale, the chief technology officer owned 166,912 shares in the company, valued at approximately $3,097,886.72. This represents a 6.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 130,571 shares of company stock valued at $2,411,026. Corporate insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CBLL. Caitong International Asset Management Co. Ltd lifted its position in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. CWM LLC grew its holdings in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after acquiring an additional 2,680 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell during the 3rd quarter valued at approximately $33,000.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $21.06 on Tuesday. The company has a market capitalization of $797.54 million, a P/E ratio of -14.33 and a beta of 0.94. CeriBell has a 1-year low of $10.85 and a 1-year high of $24.33. The firm’s 50 day simple moving average is $19.09 and its two-hundred day simple moving average is $18.18. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Research analysts expect that CeriBell will post -1.44 EPS for the current fiscal year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.